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BACKGROUND. This prospective trial was conducted to evaluate the outcome of
patients treated with preoperative and postoperative chemotherapy, mastectomy,
and irradiation for locoregionally advanced breast carcinoma.
METHODS. Between June 1986 and September 1990, 71 patients received 2 cycles
of doxorubicin that alternated with 2 cycles of cyclophosphamide, methotrexate,
and 5-fluorouracil prior to mastectomy; irradiation was administered when the
tumor was not amenable to surgical resection. Additional chemotherapy and tamoxifen, in hormone receptor-positive tumors, was used after mastectomy. Postoperative irradiation was given on a selective basis for patients at high risk for
locoregional disease recurrence.
RESULTS. Although 5 patients (7%) had disease progression, clinical partial or
complete tumor response to preoperative chemotherapy was noted in 46 patients
(65%).Sixty-eight patients (96%) underwent mastectomy. With a median followup of 52 months, the relapse-free and overall survival rates at 5 years were 42%
and 57%, respectively. Locoregional tumor recurrence occurred in 14 patients
(20%), and 28 patients (39%) developed metastatic disease. Menopausal status,
clinical presentation (noninflammatory vs. inflammatory), and American Joint
Committee on Cancer clinical stage were independent covariates associated with
patient outcome.
CONCLUSIONS. Preoperative alternating chemotherapy, with the selective use of
irradiation, resulted in significant locoregional disease regression and the successful integration of mastectomy into the therapeutic strategy. Locoregional tumor
control and relapse-free and overall survival estimates for the approach described
herein compared favorably with other contemporary reports for this condition.
Cancer 1996; 7E2520-8.0 1996 American Cancer Sociey.

KEYWORDS: breast neoplasms, chemotherapy, mastectomy, neoplasm recurrence,
pathology, prognosis, prospective studies, radiotherapy, survival rate.
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or patients managed with mastectomy or irradiation (RT) for locoregionally advanced breast carcinoma (LABC), disease relapse has been a common
occurrence.l-" As a result, treatment of this condition
evolved toward the integrated use of surgery, RT, and
systemic therapy (e.g.,chemotherapy). Although these
treatments have been combined in different ways, the
administration of systemic therapy prior to ablation
of locoregional (LR) tumor (i.e., neoadjuvant therapy)
has several possible advantages. With this approach,
there existed the potential to provide prompt treatment of occult systemic disease (i.e., micrometastases), to reduce LR tumor burden to enhance the efficacy of surgery and/or RT, and to eliminate concern
regarding stimulated micrometastatic tumor growth
after surgical removal of the primary tumor.4 On the
basis of these principles, neoadjuvant chemotherapy
was introduced into the management of LABC, and
the initial experience with this approach resulted in
favorable tumor response and patient o ~ t c o m e . " " ~
Furthermore, the results achieved with neoadjuvant
Chemotherapy may be enhanced by the use of additional chemotherapy after surgical or radiotherapeutic
treatment of the LR disease process.'
During this time, the concept of alternating noncross-resistant therapy emerged as a possible method
to improve treatment efficacy.' This concept was
based on the hypothesis that spontaneous somatic
mutation of tumors occurred during the course of
treatment. As a derivative of this hypothesis, an inverse
relationship between tumor volume and the likelihood
of cure with chemotherapy was assumed. This led to
the conclusion that a combination of noncross-resistant chemotherapy used in a rapidly alternating fashion would have the greatest probability of eradicating
all tumor cells within a heterogeneous population, and
that the malignancy should be treated as early as possible to increase the chance for cure.
In the context of these observations, the North
Central Cancer Treatment Group, in association with
the Mayo Clinic, embarked upon a prospective trial
that employed alternating noncross-resistant chemotherapy as the initial treatment of LABC. The selection
of chemotherapy was based on the results achieved
with doxorubicin in the management of metastatic
breast cancer," and the experience with the combination of cyclophosphamide, methotrexate, and 5-flU0rouracil in the adjuvant setting." After preoperative
chemotherapy, mastectomy was incorporated because
of the likelihood for residual LR disease," which might
increase the risk of LR tumor recurrence and the emergence of chemotherapy-resistant tumor cells. RT was
used to enhance LR disease control in patients with
inflammatory carcinoma, and was selectively inte-
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grated into the treatment strategy for patients with
noninflammatory disease on the basis of the histologic
findings from the mastectomy specimen.

PATIENTS AND METHODS
Patient Characteristics
Between June 1986 and September 1990, 71 women
with histologically confirmed LABC were enrolled in
a prospective study conducted by the North Central
Cancer Treatment Group (NCCTG) in collaboration
with the Mayo Clinic. These patients had one or more
of the following clinical findings: tumor more than 5
cm in diameter; tumor involvement of chest wall (ribs
or intercostal or serratus anterior muscles) or skin (ipsilateral cutaneous edema, ulceration, or satellite nodules); clinically evident inflammatory carcinoma, l 3
ipsilateral fixed axillary adenopathy; or histologic
evidence of ipsilateral internal mammary or supraclavicular lymph node involvement. Additional criteria
for trial eligibility included: age younger than 70 years;
performance score of 0- 1Is; adequate hepatic and renal function; and evaluable or measurable disease.14
The presence of any of the following conditions precluded study entry: prior breast cancer therapy; bilateral breast cancer; metastases to sites other than ipsilateral regional or supraclavicular lymph nodes; a leukocyte count of less than 4000/p,L; a platelet count of
less than 1OO,OOO/pL; concurrent pregnancy or lactation; or previous malignancy exclusive of nonmelanomatous skin carcinoma. Patients were considered
technically operable if, in the opinion of the surgeon,
all disease could be removed with primary closure
(without cutaneous or muscular transposition) without anticipated microscopic or gross tumor residua.
Of the 71 patients enrolled in this trial, all were
included in the present analysis. No patient was excluded due to trial ineligibility, cancellation, or loss to
follow-up. The pretherapy clinical characteristics of
the study group are summarized in Table 1.
Evaluation and Treatment
Prior to trial entry, patient evaluation was comprised
of history, physical examination, complete blood cell
count, chemistry profile, electrocardiography, chest
radiography, mammography, radionuclide bone scan,
and pregnancy test (if indicated). Treatment began
(Fig. 1) after informed consent was obtained as specified by Department of Health and Human Services
and institutional guidelines.
Preoperative chemotherapy was comprised of intravenous doxorubicin, 75 mglm', followed 3 weeks
later by the administration of cyclophosphamide (C),
methotrexate (MI, and 5-fluorouracil (F). The CMF
regimen consisted of cyclophosphamide, 600 mg/m"
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TABLE 1
Patient Characteristics
Inflammatory

Noninflammatory

No. of
patients

%

No. of
patients

%

31

44

40

56

16
15

52
48

20
20

50
50

6
20
5
2

19
65
16
6

6
23
10
2

15
58
25
5

No
Yes
Clinical stageh
IIB
lllA
lIlB
IV
Technically operable

0
31

0
100

25
15

63
38

O

0

0
29
2

n

3
20
15
2

8
50
38
5

No
Yes
Tumor grade

27

Characteristic
All patientsa
Menopausal status
Premenopausal
Postmenopausal
Clinical lymph node involvement
None
Mobile axillary
Fixed axillary
Supraclavicular
Clinical chest walliskin extension

1-2
3-4

Unknown
Estrogen receptor content
.I0
210

Unknow

94
6

87
13

2s

4

15

63
38

8
21
2

26
68
6

10
27
3

25
68
8

4
13
14

13
42
45

11
13
16

28
33
40

Median age, 50 yearc (range, 35-68 years).
“American loint Committee on Cancer IAICC) Sraging System.”

methotrexate, 40 mg/m2,and 5-fluorouracil, 600 mg/
m2,administered intravenously on the first and eighth
days of each &week cycle. Patient status was assessed
at each chemotherapy session as specified by World
Health Organization (WHO) guidelines.l 4 Accordingly,
clinical response was defined as follows: complete response, disappearance of all known disease; partial
regression, 50% or greater decrease in tumor area or
size; no change, less than partial regression without
progressive disease; and progressive disease, 25% or
greater increase in tumor size or appearance of new
lesions. The WHO criteria were used to grade the acute
toxicity of preoperative ~hemotherapy.’~
Treatment in
accordance with protocol specification was discontinued if disease progression occurred.
Dosage modification of all chemotherapeutic
agents was made for severe nausea or vomiting (20%
reduction), and for hepatic or hematologic toxicity. At
the time of scheduled retreatment, therapy was de-

\
Nonop.Dls
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FIGURE 1. Treatment scheme. DOX: doxorubicin, CMF: cyclophosphamide. methotrexate, 5-fluorouracil, RT: irradiation. ‘Inflammatory presentation; or residual tumor 1 5 cm diameter; or involvement of skin, fascia,
2 4 axillary lymph nodes, or surgical rnargin(s). $Gross residual disease
or microscopic involvement of surgical margin@). ‘If hormone receptor
positive.

layed if serum aspartate aminotransferase was more
than 3 times the upper normal value, if serum total
bilirubin was more than twice the upper normal value,
if the leukocyte count was < 3000/pL, or if the platelet
count was < lOO,OOO/pL. Modifications according to
the hematologic nadir value of preceding cycles included a 20% dosage increase for a leukocyte count of
> 3000/yL and a platelet count of > 100,000pL, a 20%
decrease for a leukocyte count of lOOO/pL to 1500/,~~L
or a platelet count of 25,0001pL to 75,OOO/pL, and a
30% decrease for a leukocyte count of < lO0OlpL or
a platelet count of < 25,00O/yL. In addition, the dosage of doxorubicin, methotrexate, and 5-fluorouracil
was reduced for moderate (20% reduction) or severe
(30%reduction) stomatitis or diarrhea. The dosage of
methotrexate was reduced or discontinued in the presence of renal toxicity.
After two cycles of doxorubicin that alternated
with two cycles of CMF, disease status was re-evaluated, and modified radical mastectomy (MRM) was
performed in those patients regarded as technically
operable. Patients with inflammatory presentation or
those with histologic evidence of residual tumor that
measured more than 5 cm in diameter, or with
involvement of skin, fascia, 4 or more axillary lymph
nodes, or surgical margin(s1 in the MRM specimen
were considered at high risk for LR disease recurrence.
For these patients, RT concurrent with two cycles of
CMF was administered and followed with additional
doxorubicin and CMF chemotherapy (Fig. 1). For patients considered at low risk for LR recurrence, two
postoperative cycles of doxorubicin that alternated
with two cycles of CMF were given.
When the tumor was not considered amenable to
complete surgical resection after preoperative chemotherapy, RT concomitant with two cycles of CMF was
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used (Fig. 1 ) . Thereafter, if MRM was performed with
favorable margins (no evidence of gross tumor residua
or microscopic involvement of surgical margins), three
additional cycles of chemotherapy were administered.
When MRM could not be performed or when unfavorable margins existed after MRM, the patient went off
study and was managed as indicated by clinical circumstance.
When given prior to mastectomy, the RT target
volume consisted of the breast and chest wall, and
the ipsilateral internal mammary, supraclavicular, and
axillary lymph node regions. Megavoltage equipment
was used to administer 50.4 Gray (Gy) in 28 daily fractions over 5.5 weeks; an additional 10-15 Gy in 5-8
treatments was given to clinically apparent supraclavicular or internal mammary adenopathy. Similar
methods were used to administer postoperative RT,
although the mastectomy scar received an additional
10 Gy in 5-6 daily treatments. All patients in whom
RT was initiated completed treatment and received
the intended irradiation dosage.
After completion of all therapy, patients were assessed every 3 months for 3 years, every 6 months
during the next 2 years, and yearly thereafter. Sites
of initial tumor progression were classified as local
(ipsilateral chest wall), regional (ipsilateral supraclavicular, infraclavicular, axillary or internal mammary
lymph nodes), or distant (all other sites). The classification for any patient with simultaneous local or regional and distant tumor relapse was distant.

Method of Analysis
Relapse-free survival (RFS) and overall survival (0s)
were determined from the date of registration to the
date of treatment failure or death. For analysis of RFS,
an event was defined as recurrence of breast carcinoma, and patients who died without evidence of disease recurrence were censored; death from any cause
was considered an event for evaluation of 0s. The
method of Kaplan and Meier was used to estimate the
duration of RFS and of 0S.l5 In analysis of outcome,
the observed (crude) rate for the event under consideration was determined for each factor, and univariate
comparisons of end points were made with the log
rank statistic. l6 Multivariate analysis employed the Cox
proportional hazard model to find the most significant
factors related to outcome,” and variables were retained on the basis of the backward elimination procedure. A two-sided P value of 5 0.05 was considered
significant.

RESULTS
Toxicity of Preoperative Chemotherapy
Preoperative chemotherapy produced myelosuppression in all but 1 patient (99%). Although 46 patients
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(65%) had a leukocyte nadir of < 2,0001pL (Grade 3
or 4), only 3 patients (4.2%)had a minor-to-moderate
(Grade 1 or 2) infectious complication and only 1 patient (1.4%) experienced a major (Grade 3) infection.
Thrombocytopenia (a platelet count of < 130,OOO/yL)
occurred in 32 patients (45%),but a platelet nadir of
< 50,OOO/p,L(Grade 3 or 4) was noted in only 6 patients
(8%)and no hemorrhagic complications developed.
No deaths occurred as a result of hematologic toxicity.
Significant nonhematologic side effects were limited
to vomiting (61%) that was severe (Grade 3) in 4 patients (6%), and oropharyngeal mucositis and/or
esophagitis that was evident in 33 patients (46%),but
was moderate (Grade 2) in 8 patients (11%)and severe
(Grade 3) in only 1 patient (1.4%).No life-threatening
or lethal nonhematologic complications occurred.
Among patients without tumor progression during
preoperative chemotherapy (66 patients), 60 patients
(91%) received 2 85% of the intended doxorubicin
dose (median, 99%), and 2 85% of the planned
amount of CMF chemotherapy was administered to
50 patients (76%)(median, 98%).This compared favorably with the percentage intended dose administered
thereafter, which for doxorubicin and for CMF was 2
85% in 69% of patients (median, 94%) and 63% of
patients (median, 79%),respectively.

Response to Preoperative Chemotherapy
As shown in Table 2, partial or complete clinical response to preoperative chemotherapy was observed
in 46 patients (65%). Among 52 patients considered
unresectable at presentation, 40 (77%) were deemed
operable after preoperative chemotherapy and underwent MRM, whereas 10 patients also received RT with
2 concurrent cycles of CMF prior to MRM. Eighteen
of 19 patients amenable to surgical resection at presentation were able to undergo MRM after chemotherapy. However, disease progression occurred in 5 patients (7%), including l patient considered operable
at the tim’e of registration, and 3 patients with noninflammatory carcinoma went off study because the extent of LR disease progression (2 patients) or the development of distant metastases precluded surgical intervention (1 patient). Therefore, 68 of the 71 patients
(96%) entered on the trial underwent MRM, and 53
patients (75%)were managed solely with chemotherapy prior to surgical resection. Among these 53 patients, the histologic findings of the MRM specimen
placed 26 (49%)at high risk for LR tumor recurrence.
For the 40 patients with noninflammatory clinical
presentation, 37 underwent MRM; of these, 29 (78%)
had a partial or complete response to preoperative
chemotherapy. However, 10 patients (35%) were at
high risk for LR disease recurrence based on findings
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TABLE 2
Clinical Response to Preoperative Chemotherapy
Inflammatory

No. of
patients

Response
Complete
Partial
No cliatige
Procression

%

No. of
patients
11
35

10

8

20

45
39
6

21
8

53
20

20

3

8

5

8

01

%

14

12

--

No. of
patients

3

2

20-

AU patients

Noninflammatory

Relwsafreasurvival
Overall survival
I

from histologic examination of the MRM specimen.
Likewise, 8 patients (22%)had no change to preoperative chemotherapy, and 4 patients (50%) remained in
the high risk category after MRM. Therefore, of the 37
patients with noninflammatory clinical presentation
managed with MRM, 14 (38%)had histologic characteristics that placed the patient in the high risk category, and 13 patients received postoperative RT (one
patient refused RT) on this basis.

%
15

49
28
7

in Table 3 . Of note, the LR recurrence risk categories
were not associated with LR tumor recurrence as an
initial and sole site (perhaps because the high risk
group received RT), but there was an association with
metastatic disease relapse.
Patient and tumor-related characteristics were evaluated to determine the impact of selected pretherapy
factors on treatment outcome. The variables selected
for inclusion in a univariate analysis were menopausal
status, clinical presentation, American Joint Committee
on Cancer (AJCC) clinical ~ t a g e ,operability
'~
at presentation, and the presence of fixed axillary adenopathy. Estrogen receptor content was not included because the
diagnostic biopsy did not recover a sufficient amount of
tumor for quantification in a sizable proportion of patients (42%).Although operability and fixed axillary adenopathy were not associated with either RFS or OS, all
other characteristics approached or met statistical significance as factors predictive of disease outcome, as
shown in Table 4. A significant difference in outcome
between AJCC Stage IIIA and Stage IIIB was maintained
with exclusion of AJCC Stage IIB and IV disease categories (data not shown).
Multivariate analysis preserved the significance of
menopausal status, clinical presentation, and AJCC
clinical stage as independent covariates.

DISCUSSION
Disease Outcome
With median follow-up of 52.2 months (range, 10.9 to
89.9 months), tumor relapse occurred in 42 patients
(59%),and 37 patients (52%) had died. The actuarial
estimate of RFS and 0s for all patients at 5 years was
42% and 57%, respectively (Fig. 2). Fourteen patients
(20%)had LR recurrence as the initial and sole site of
treatment failure, whereas 28 patients (39%)had initial
disease relapse at a distant site(s).The distribution of
initial sites of treatment failure according to clinical
presentation, clinical response to preoperative chemotherapy, and LR recurrence risk category are presented

The overall tumor stage distribution of patients with
breast cancer has changed over the last several years.
Indeed, the proportion of patients with LABC (i.e.,
AJCC Stage 111) has shown modest decline over time,
and now accounts for approximately 7% of patients
with newly recognized breast carcinoma.18In addition
to this relatively low incidence rate, LABC is also a
heterogeneous condition in which patient characteristics and tumor-related factors have been predictive of
disease outcome. For these reasons, prospective investigations of this condition have been somewhat limited, and the preferred management scheme for the
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TABLE 3
Initial Sites of Disease Relapse in LocoregionallyAdvanced Breast Carcinoma

LR recurrence
Characteristic
Clinical presentation
Inflammatory
Noninflammatory
Clinical response
Partial or complete
No change
Progression
LR recurrence riskh
Low
High

Distant metastasis

Any relapse

No. of
patients

No. of
patients

%

P value

No. of
patients

%

Pvalue

No. of
patients

%

P value

31
40

8
6

26
15

0.22

14
14

45
35

0.39

22
20

71
50

0.07

46
20
5

3
7
4

7
35
80

21
6
1

46
30
20

24
13
5

52
65
100

22
46

4

8

18
17

3
24

14
52

7
32

70

0.003a

0.94

0.23a

0.002

0.33a

32

0.003

1.R: I.ocoregioiial.

“Analysisrestricted IO partial or complete response versus no change; results not affected by inclusion of patients with disease progression (data not shown)
’Three patients who did not undergo mastectomy were excluded.
All patients had intlammatoly presentation.

TABLE 4
Impact of Pretherapy Disease Characteristics on Outcome in LocoregionallyAdvanced Breast Carcinoma
Relapse-free survival
Characteristic
Menopausal status
Premenopausal
Postmenopausal
Clinical presentation
Inflammatory
Noninflarnmatory
Clinical stage”
IIB
IIIA
lIlB
1v

Overall survival

No. of
patients

5-y,%

Median, mo

P value

5-y,%

Median, mo

P value

36
35

50
34

47.2
25.8

0.08

69
45

57.1
48.4

0.03

31
40

26
54

25.3
60.5

0.06

48
64

46
76.3

0.15

3
20
44
4

33
54
41
0

15.2
60.5
38.3
10.1

0.0005

33
65
61
0

36.1
79.3
65.5
11.2

< 0.0001

’ American Joint Committee on Cancer (AICC) Staging System.”

patient with LARC has not been defined through contemporaneous trials of a comparative study design.
The present study was conducted to prospectively
evaluate a therapeutic approach predicated on the hypothesis that tumor mutation to a drug-resistant state
may occur during treatment.g Therefore, an alternating noncross-resistant chemotherapy regimen was incorporated into a multimodality program in an attempt to minimize the likelihood that treatment-refractory tumor clonogens would emerge. Furthermore,
chemotherapy was administered as the initial component of a therapeutic approach designed to provide a

reduction in LR tumor burden and prompt treatment
of potential micrometastases. Although this study
could not determine the relative efficacy of this approach, the toxicity profile, clinical tumor response,
and relapse-free survival and overall survival rates described herein were comparable to treatment programs that administer chemotherapy in a conventional manner19-28as well as in the setting of “hormonal ~ynchronization.”~~-~’
The preoperative chemotherapy program used
herein resulted in complete or partial tumor response
in two-thirds of patients, which was comparable to
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ical stage, assigned in accordance with the AJCC sysresults achieved in similar studies of preoperative chetem,I3was the most striking factor associated with remotherapy for LABC.",24,26.27.29".JE.33
Although an associlapse-free and overall survival. This confirmed the obation between clinical response and LR tumor control
servation of other i n v e ~ t i g a t o r s , ~
and
~ . ~provided
~
was observed, the metastatic relapse rate was not affurther support for subdivision of the Stage I11 category
fected by clinical appraisal of tumor response at the
and consideration of ipsilateral supraclavicular adeprimary site (Table 3). However, these observations
nopathy as a metastatic site.'8.40Likewise, the adverse
must be viewed with caution because clinical response
impact of postmenopausal status and inflammatory
criteria may not reliably predict ultimate disease outclinical presentation on patient outcome confirmed
come.26.34
Furthermore, a trial of larger scope would
the findings of prior investigations."-71.24,25,29These facbe required to accurately evaluate the association of
tors should be considered in the development and
primary tumor response with the metastasis free
interpretation of clinical trials addressing newer therarate."5Nonetheless, it was noteworthy that tumor propeutic strategies for the management of LABC.
gression was uncommon (7%) during preoperative
This study represents one of the few clinical expechemotherapy, and three-quarters of patients with inriences of alternating noncross-resistant chemotheroperable disease responded to preoperative chemoapy in the care of patients with high risk breast cancer.
therapy and the selective use of RT in a manner that
Although the design of a Belgium trial was similar to
allowed incorporation of mastectomy into the therathat reported herein,32the Eastern Cooperative Oncolpeutic scheme.
ogy Group (ECOG) study of partially noncross-resisAfter initial chemotherapy (with or without preoptant chemohormonal therapy for premenopausal paerative RT), mastectomy was incorporated because it
tients with lymph node positive Stage I1 breast cancer"'
~ , ~ ~ increase
was believed residual LR d i ~ e a s e ' might
was
a prospective comparative trial that was in part
the risk for disease relapse. Although this approach
based
on assumptions central to the Goldie-Coldman
produced satisfactory LR disease control, breast-conhypothe~is.~
Although the ECOG investigation sugserving surgery may be a feasible alternative for the
gested
a
therapeutic
benefit with the alternating appatient with a favorable response to the preoperative
proach, the trial design included other variables that
chemotherapy ~ r o g r a m , ~ 'and
, ~ ~ merits
, ~ ~ considermay explain this observation. Indeed, this finding may
ation in future clinical trials for LABC. In an effort to
be attributed to the use of doxorubicin and/or fluoximprove disease control, RT was used in patients with
ymesterone in the alternating, but not the convenclinical inflammatory breast cancer, and selectively on
tional, regimen, rather than the method of treatment
the basis of postmastectomy histologic findings in
administration. Therefore, currently available clinical
those with noninflammatory presentation. Although
trials have not provided a definitive test of a hypothesis
the number of patients available for analysis did not
generated more than a decade ago.
allow definitive conclusion, omission of RT in the low
Although this report described patient outcome
risk group did not result in an excessive rate of recurthat followed a therapeutic strategy predicated on a
rence at a LR site(s). Similarly, use of RT in the high
certain model of tumor growth and treatment responrisk cohort appeared to achieve satisfactory LR tumor
siveness,' other hypotheses to explain chemotherapy
control. However, analysis of initial, solitary sites of
resistance have been put forth. An alternative model
disease relapse may underestimate the likelihood of
residual LR disease and the risk for tumor rec~rrence.~' suggested that a tumor is comprised of subclones with
varied growth kinetics and different profiles of chemoFurthermore, all patients in the high risk group who
therapy re~istance.~'
Adherence to this model sugexperienced LR tumor recurrence presented with clingested that the initial treatment should be adminisical inflammatory disease. Therefore, approximately
tered in a continuous (i.e., uninterrupted) fashion
one-quarter of those patients with clinical inflammaagainst the more rapidly growing tumor subclone(s1.
tory breast carcinoma experienced LR recurrence as
Thereafter, a noncross-resistant agent or combination
the first and only site of disease recurrence despite the
effective against the slower growing and/or resistant
combined use of chemotherapy, mastectomy, and RT.
subclone(s) should be given. Although this hypothesis
For this disorder, alternative methods of RT administration, such as accelerated h y p e r f r a c t i o n a t i ~ n or
, ~ ~ , ~has
~ not been tested in the context of LABC, comparative clinical trials in lymph node positive, Stage I1
the use of innovative surgical or chemotherapeutic3'
breast cancer have been conducted. The Cancer and
approaches require investigation in an attempt to imLeukemia Group B (CALGB) demonstrated an improve LR tumor control.
proved outcome when a doxorubicin-based combinaThe influence of pretherapy characteristics on distion was administered after CMF with vincristine and
ease outcome was also of interest and was evaluated
predni~one.'~
However, as in the ECOG trial,41the benwithin the context of this clinical trial. The overall clin-
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eficial effect noted with sequential therapy may have
been due to the addition of doxorubicin and/or fluoxyme st er on e.
The Instituto Nazionale Tumori (Milan, Italy) provided a more direct test of the alternating versus sequential treatment approach and the assumptions derived from their respective biologic
This
randomized study compared two sequences of noncross-resistant chemotherapy, namely, CMF alternating with doxorubicin (alternating therapy) and doxorubicin followed by CMF (sequential therapy). Relapse-free survival and overall survival comparisons
demonstrated improved results with the sequential
therapy approach. Although both chemotherapy regimens included the same agents, dosages, treatment
duration, and overall drug dose intensity, the doxorubicin dose intensity was higher for those patients assigned to sequential therapy. Therefore, the advantage
attributed to the sequential approach may have been
related to doxorubicin dose intensity rather than the
sequence of noncross-resistant chemotherapy that
was administered. The results of ongoing clinical research efforts may resolve questions of this nature.
In conclusion, the treatment strategy described
herein provided a therapeutic outcome for patients with
LABC that compared favorably with other contemporary
investigations. Although this approach merits consideration for the care of these patients, further research efforts that adopt innovative s ~ r g i c a l ,radiotherapeu~~.~~
tic?7,38
and systemic treatment3’~~~
measures are required
to effect a much needed improvement for the outcome
of patients with this condition.
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